Scientific opinion on the safety of monacolins in red yeast rice

Abstract The Panel on Food Additives and Nutrient Sources added to Food (ANS) was asked to deliver a scientific opinion on the safety of monacolins in red yeast rice (RYR) and to provide advice on a dietary intake of monacolins that does not give rise to concerns about harmful effects to health. The Panel reviewed the scientific evidences available as well as the information provided by interested parties in response of a public ‘Call for data’ launched by EFSA. The Panel considered that monacolin K in lactone form is identical to lovastatin, the active ingredient of several medicinal products authorised for the treatment of hypercholesterolaemia in the EU. On the basis of the information available, the Panel concluded that intake of monacolins from RYR via food supplements, could lead to estimated exposure to monacolin K within the range of the therapeutic doses of lovastatin. The Panel considered that the available information on the adverse effects reported in humans were judged to be sufficient to conclude that monacolins from RYR when used as food supplements were of significant safety concern at the use level of 10 mg/day. The Panel further considered that individual cases of severe adverse reactions have been reported for monacolins from RYR at intake levels as low as 3 mg/day. The Panel concluded that exposure to monacolin K from RYR could lead to severe adverse effects on musculoskeletal system, including rhabdomyolysis, and on the liver. In the reported cases, the product contained other ingredients in addition to RYR. However, these reported effects in particular musculoskeletal effects, have both occurred after ingestion of monacolin K and lovastatin independently. On the basis of the information available and several uncertainties highlighted in this opinion, the Panel was unable to identify a dietary intake of monacolins from RYR that does not give rise to concerns about harmful effects to health, for the general population, and as appropriate, for vulnerable subgroups of the population.

[1]  Peijie Chen,et al.  A case of erectile dysfunction induced by red yeast rice in lipid‐lowering therapy , 2018, Phytotherapy research : PTR.

[2]  I. Khan,et al.  Variability in strength of red yeast rice supplements purchased from mainstream retailers , 2017, European journal of preventive cardiology.

[3]  E. Raschi,et al.  Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system , 2017, British journal of clinical pharmacology.

[4]  M. Perri,et al.  When Nutraceuticals Reinforce Drugs Side Effects: A Case Report. , 2016, Current drug safety.

[5]  M. Jean-Pastor,et al.  Atteintes musculaires et levure de riz rouge : analyse des données de la base nationale de pharmacovigilance et revue de la littérature ☆ , 2016 .

[6]  A. Hahn,et al.  Low daily dose of 3 mg monacolin K from RYR reduces the concentration of LDL-C in a randomized, placebo-controlled intervention. , 2016, Nutrition research.

[7]  B. Venhuis,et al.  Pharmacologically effective red yeast rice preparations marketed as dietary supplements illustrated by a case report. , 2016, Drug testing and analysis.

[8]  C. Guy,et al.  [Red yeast-rice-induced muscular injuries: Analysis of French pharmacovigilance database and literature review]. , 2016, Therapie.

[9]  Fusheng Chen,et al.  Edible Filamentous Fungi from the Species Monascus: Early Traditional Fermentations, Modern Molecular Biology, and Future Genomics , 2015 .

[10]  V. Gerdes,et al.  Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain - a systematic review and meta-analysis. , 2015, Atherosclerosis.

[11]  Frances M. Burke.  Red Yeast Rice for the Treatment of Dyslipidemia , 2015, Current Atherosclerosis Reports.

[12]  J. Neher,et al.  Clinical inquiry: is red-yeast rice a safe and effective alternative to statins? , 2015, The Journal of family practice.

[13]  H. Monteiro,et al.  Treatment of Dyslipidemia with Statins and Physical Exercises: Recent Findings of Skeletal Muscle Responses. , 2015, Arquivos brasileiros de cardiologia.

[14]  I. Khan,et al.  Chemical profiling and quantification of monacolins and citrinin in red yeast rice commercial raw materials and dietary supplements using liquid chromatography-accurate QToF mass spectrometry: Chemometrics application. , 2014, Journal of pharmaceutical and biomedical analysis.

[15]  Cesare R Sirtori,et al.  The pharmacology of statins. , 2014, Pharmacological research.

[16]  Long Jiang,et al.  A Meta-Analysis of Red Yeast Rice: An Effective and Relatively Safe Alternative Approach for Dyslipidemia , 2014, PloS one.

[17]  D. Shih,et al.  Incidence of citrinin in red yeast rice and various commercial Monascus products in Taiwan from 2009 to 2012 , 2014 .

[18]  D. Popovich,et al.  Red azaphilone pigments extracted from red yeast rice induces cellular senescence and reduces viability in HepG2 cells , 2013 .

[19]  A. S. Vidyarthi,et al.  A review on lovastatin and its production , 2013 .

[20]  J. DiNicolantonio,et al.  Red yeast rice for dysipidemia. , 2013, Missouri medicine.

[21]  B. Nigović,et al.  Simultaneous determination of lovastatin and citrinin in red yeast rice supplements by micellar electrokinetic capillary chromatography. , 2013, Food chemistry.

[22]  R. Beckett,et al.  Peripheral neuropathy induced by red yeast rice in a patient with a known small bowel gastrointestinal tumour , 2013, BMJ Case Reports.

[23]  Jyh-Chin Yang,et al.  Improved dissolution rate and oral bioavailability of lovastatin in red yeast rice products. , 2013, International journal of pharmaceutics.

[24]  Efsa Panel on Dietetic Products.  Scientific Opinion on the substantiation of a health claim related to monacolin K in SYLVAN BIO red yeast rice and maintenance of normal blood LDL-cholesterol concentrations pursuant to Article 13(5) of Regulation (EC) No 1924/2006 , 2013 .

[25]  Ana Mornar,et al.  Development of a rapid LC/DAD/FLD/MS(n) method for the simultaneous determination of monacolins and citrinin in red fermented rice products. , 2013, Journal of agricultural and food chemistry.

[26]  P. Patakova.  Monascus secondary metabolites: production and biological activity , 2013, Journal of Industrial Microbiology & Biotechnology.

[27]  Jyh-Chin Yang,et al.  Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin , 2012, Evidence-based complementary and alternative medicine : eCAM.

[28]  T. Weir,et al.  Fermented foods: patented approaches and formulations for nutritional supplementation and health promotion. , 2012, Recent patents on food, nutrition & agriculture.

[29]  S. Saeger,et al.  Scientific Opinion on the risks for public and animal health related to the presence of citrinin in food and feed , 2012 .

[30]  Efsa Panel on Dietetic Products.  Scientific Opinion on the substantiation of health claims related to monacolin K from red yeast rice and maintenance of normal blood LDL cholesterol concentrations (ID 1648, 1700) pursuant to Article 13(1) of Regulation (EC) No 1924/2006 , 2011 .

[31]  David J. Becker,et al.  Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! , 2010, Archives of internal medicine.

[32]  T. Hagve,et al.  HypoCol (red yeast rice) lowers plasma cholesterol – a randomized placebo controlled study , 2010, Scandinavian cardiovascular journal : SCJ.

[33]  N. Ayoub,et al.  Azaphilones: a class of fungal metabolites with diverse biological activities , 2010, Phytochemistry Reviews.

[34]  David J. Becker,et al.  Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients , 2009, Annals of Internal Medicine.

[35]  M. Pompili,et al.  Acute hepatitis caused by a natural lipid-lowering product: when "alternative" medicine is no "alternative" at all. , 2009, Journal of hepatology.

[36]  Josef Schlatter,et al.  Transparency in Risk Assessment - Scientific Aspects Guidance of the Scientific Committee on Transparency in the Scientific Aspects of Risk Assessments carried out by EFSA. Part 2: General , 2009 .

[37]  J. Kocher,et al.  Symptomatic hepatitis associated with the use of herbal red yeast rice. , 2008, Annals of internal medicine.

[38]  A. Vannacci,et al.  Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products. , 2008, British journal of clinical pharmacology.

[39]  C. Ballantyne,et al.  A case report of myopathy from consumption of red yeast rice. , 2008, Journal of clinical lipidology.

[40]  Nan-Wei Su,et al.  Biologically active components and nutraceuticals in the Monascus-fermented rice: a review , 2008, Applied Microbiology and Biotechnology.

[41]  C. Liu,et al.  Efficacy of Monascus purpureus Went rice on lowering lipid ratios in hypercholesterolemic patients , 2007, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[42]  P. Mueller.  Symptomatic myopathy due to red yeast rice. , 2006, Annals of internal medicine.

[43]  T. Mongini,et al.  CHINESE RED RICE DEPLETES MUSCLE COENZYME Q10 AND MAINTAINS MUSCLE DAMAGE AFTER DISCONTINUATION OF STATIN TREATMENT , 2006, Journal of the American Geriatrics Society.

[44]  G. Eisenbrand.  Toxicological evaluation of red mould rice. , 2006, Molecular nutrition & food research.

[45]  N. Seeram,et al.  Plasma clearance of lovastatin versus chinese red yeast rice in healthy volunteers. , 2005, Journal of alternative and complementary medicine.

[46]  Tsai-Chung Li,et al.  Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia. , 2005, European journal of endocrinology.

[47]  Fusheng Chen,et al.  Study on red fermented rice with high concentration of monacolin K and low concentration of citrinin. , 2005, International journal of food microbiology.

[48]  Michael Schachter,et al.  Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update , 2005, Fundamental & clinical pharmacology.

[49]  T. Pan,et al.  Modified mutation method for screening low citrinin-producing strains of Monascus purpureus on rice culture. , 2004, Journal of agricultural and food chemistry.

[50]  Zheng-Tao Wang,et al.  Identification and chemical profiling of monacolins in red yeast rice using high-performance liquid chromatography with photodiode array detector and mass spectrometry. , 2004, Journal of pharmaceutical and biomedical analysis.

[51]  J. MacDonald,et al.  The Toxicology of HMG—CoA Reductase Inhibitors: Prediction of Human Risk , 2004, Toxicologic pathology.

[52]  K. Olive,et al.  Chinese Red Rice-induced Myopathy , 2003, Southern medical journal.

[53]  G. Prasad,et al.  Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. , 2002, Transplantation.

[54]  C. Stancu,et al.  Statins: mechanism of action and effects , 2001, Journal of cellular and molecular medicine.

[55]  A. Gotto,et al.  Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. , 2001, The American journal of cardiology.

[56]  D. Zhang,et al.  Constituents of red yeast rice, a traditional Chinese food and medicine. , 2000, Journal of agricultural and food chemistry.

[57]  P. Elsner,et al.  Anaphylaxis due to Monascus purpureus‐fermented rice (red yeast rice) , 1999, Allergy. European Journal of Allergy and Clinical Immunology.

[58]  M. Sabater-Vilar,et al.  Mutagenicity of commercial Monascus fermentation products and the role of citrinin contamination. , 1999, Mutation research.

[59]  R. Elashoff,et al.  Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. , 1999, The American journal of clinical nutrition.

[60]  V. Havlíček,et al.  Biological activities of oligoketide pigments of Monascus purpureus. , 1999, Food additives and contaminants.

[61]  P. Neuvonen,et al.  Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid , 1998, Clinical pharmacology and therapeutics.

[62]  H. Lennernäs,et al.  Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors , 1997, Clinical pharmacokinetics.

[63]  M Vuelta,et al.  [Food-drug interactions]. , 1997, Enfermeria intensiva.

[64]  W. O’Neill,et al.  Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. , 1994, The New England journal of medicine.

[65]  C. Furberg,et al.  Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. , 1994, Circulation.

[66]  D. Hunninghake,et al.  Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[67]  A. Y. Lu,et al.  Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. , 1991, Archives of biochemistry and biophysics.

[68]  A. Serajuddin,et al.  Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. , 1991, Journal of pharmaceutical sciences.

[69]  C. Shear,et al.  Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin. , 1991, The American journal of medicine.

[70]  W. F. Hoffman,et al.  Biotransformation of lovastatin. I. Structure elucidation of in vitro and in vivo metabolites in the rat and mouse. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[71]  D. E. Duggan,et al.  Biotransformation of lovastatin. II. In vitro metabolism by rat and mouse liver microsomes and involvement of cytochrome P-450 in dehydrogenation of lovastatin. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[72]  I. Chen,et al.  The physiological disposition of lovastatin. , 1989, Drug Metabolism And Disposition.

[73]  J. L. Smith,et al.  Metabolism of lovastatin by rat and human liver microsomes in vitro. , 1988, Drug metabolism and disposition: the biological fate of chemicals.

[74]  D. Hawksworth,et al.  A new taxonomy for Monascus species based on cultural and microscopical characters , 1983 .

[75]  R Monaghan,et al.  Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[76]  W. Fishbein,et al.  Purification and Properties of an Enzyme in Human Blood and Rat Liver Microsomes Catalyzing the Formation and Hydrolysis of γ-Lactones II. METAL ION EFFECTS, KINETICS, AND EQUILIBRIA , 1966 .

[77]  W. Fishbein,et al.  Purification and properties of an enzyme in human blood and rat liver microsomes catalyzing the formation and hydrolysis of gamma-lactones. II. Metal ion effects, kinetics, and equilibra. , 1966, The Journal of biological chemistry.